{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:59Z","timestamp":1740144059430,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA-DI-2015-1297"],"award-info":[{"award-number":["HRA-DI-2015-1297"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2121-2","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T08:14:15Z","timestamp":1503562455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Penicillin for the Emergency Department Outpatient treatment of CELLulitis (PEDOCELL) trial: update to the study protocol and detailed statistical analysis plan (SAP)"],"prefix":"10.1186","volume":"18","author":[{"given":"Fiona","family":"Boland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Quirke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinead","family":"Plunkett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Eustace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor","family":"Deasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-2388","authenticated-orcid":false,"given":"Abel","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"issue":"1","key":"2121_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-9-66","volume":"9","author":"K Dwan","year":"2008","unstructured":"Dwan K, et al. Reporting of clinical trials: a review of research funders\u2019 guidelines. Trials. 2008;9(1):1.","journal-title":"Trials"},{"issue":"1","key":"2121_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-14-164","volume":"14","author":"M Quirke","year":"2013","unstructured":"Quirke M, et al. Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis: study protocol for a randomised controlled trial. Trials. 2013;14(1):1.","journal-title":"Trials"},{"issue":"7","key":"2121_CR3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0149-2918(02)80024-8","volume":"24","author":"AD Bucko","year":"2002","unstructured":"Bucko AD, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400\u00a0mg BID with either cefuroxime 250\u00a0mg BID or cefadroxil 500\u00a0mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther. 2002;24(7):1134\u201347.","journal-title":"Clin Ther"},{"issue":"3","key":"2121_CR4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/600296","volume":"49","author":"B Spellberg","year":"2009","unstructured":"Spellberg B, et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis. 2009;49(3):383\u201391.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2121_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"key":"2121_CR6","doi-asserted-by":"publisher","unstructured":"Kilburn SA, et al. Interventions for cellulitis and erysipelas. 2010. Cochrane Database of Systematic Reviews. 2010;(6). doi:\n10.1002\/14651858.CD004299.pub2\n\n.","DOI":"10.1002\/14651858.CD004299.pub2"},{"issue":"6","key":"2121_CR7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1469-0691.2012.03914.x","volume":"19","author":"BY Lee","year":"2013","unstructured":"Lee BY, et al. The economic burden of community\u2010associated methicillin\u2010resistant Staphylococcus aureus (CA\u2010MRSA). Clin Microbiol Infect. 2013;19(6):528\u201336.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2121_CR8","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1507476","volume":"374","author":"DA Talan","year":"2016","unstructured":"Talan DA, et al. Trimethoprim-sulfamethoxazole versus placebo for uncomplicated skin abscess. N Engl J Med. 2016;374(9):823\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"2121_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D\u2019Agostino","year":"2003","unstructured":"D\u2019Agostino RB, Massaro JM, Sullivan LM. Non\u2010inferiority trials: design concepts and issues\u2014the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169\u201386.","journal-title":"Stat Med"},{"issue":"24","key":"2121_CR10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594\u2013604.","journal-title":"JAMA"},{"issue":"1","key":"2121_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-1-2","volume":"1","author":"D Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol. 2001;1(1):1.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2121_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-6-148","volume":"6","author":"AJ Storck","year":"2006","unstructured":"Storck AJ, et al. Development of a health-related quality of life questionnaire (HRQL) for patients with extremity soft tissue infections (ESTI). BMC Infect Dis. 2006;6(1):1.","journal-title":"BMC Infect Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T08:14:19Z","timestamp":1503562459000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2121-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2121"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2121-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2017,8,24]]},"article-number":"391"}}